RAC 4.02% $1.79 race oncology ltd

Cardioprotection thread, page-387

  1. 916 Posts.
    lightbulb Created with Sketch. 10363
    I definitely don’t want to put too much stock into my analysis, as we just simply do not have the data, but I’m unsure what you mean about inhibitors of these gene targets not providing cardioprotection. Maybe you meant the complete cardiosynergy function, which of course there are none.

    This is the recent data that I could find about compounds targeting each of these gene pathways for Ca2+ homeostasis.

    https://hotcopper.com.au/data/attachments/6090/6090759-046a172aad179d80944c60e41c363c88.jpg

    While they might not provide anti-cancer benefits, they certainly seem to provide a mechanism of cardioprotection. I find Ruxolitinib interesting in this list, as it is a Janus Kinase Inhibitor. The Doan paper found Peficitinib, a Janus and tyrosine kinase inhibitor, was cardiotoxic. Maybe Ruxolitinib would be on this list if it were not for it's efficacy on CaMKII.

    https://hotcopper.com.au/data/attachments/6090/6090773-e95a764b388fffe3c7f1244745297900.jpg
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.79
Change
-0.075(4.02%)
Mkt cap ! $304.8M
Open High Low Value Volume
$1.86 $1.86 $1.76 $348.2K 192.6K

Buyers (Bids)

No. Vol. Price($)
1 5612 $1.77
 

Sellers (Offers)

Price($) Vol. No.
$1.79 3567 1
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
$1.78
  Change
-0.075 ( 5.38 %)
Open High Low Volume
$1.81 $1.86 $1.76 27553
Last updated 15.55pm 14/06/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.